Pityriasis rubra pilaris after Vaxzevria® COVID-19 vaccine.

J Eur Acad Dermatol Venereol

Dermatology Department, Hospital Universitario de la Princesa, Madrid, Spain.

Published: December 2021

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447033PMC
http://dx.doi.org/10.1111/jdv.17542DOI Listing

Publication Analysis

Top Keywords

pityriasis rubra
4
rubra pilaris
4
pilaris vaxzevria®
4
vaxzevria® covid-19
4
covid-19 vaccine
4
pityriasis
1
pilaris
1
vaxzevria®
1
covid-19
1
vaccine
1

Similar Publications

Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia and acute lymphoblastic leukemia, can cause rare cutaneous side effects. In this case, a 63-year-old woman developed a pityriasis rubra pilaris-like eruption 1 month after starting the drug. The skin reaction improved with dose reduction and recurred more mildly at a lower dose.

View Article and Find Full Text PDF

Background: Erythroderma is a dermatologic condition characterized by widespread red and scaly skin. The causes include, but are not limited to, psoriasis, eczema, drug eruptions, pityriasis rubra pilaris (PRP), and cutaneous T-cell lymphoma. Most of these are typified by Type 2 (e.

View Article and Find Full Text PDF

Background: While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated IL-23 levels. The purpose of this review is to summarize and interpret the literature surrounding the off-label uses of IL-23 inhibitors in dermatologic practice.

Methods: We conducted searches on PubMed and for clinical trials, observational studies, case series, and case reports assessing use of the three IL-23 inhibitors for non-psoriatic dermatologic conditions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!